Gossamer Bio, Inc. (GOSS)

Gossamer Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	114.7	-	-	-	-
Gross Profit	114.7	-	-	-	-
Selling, General & Admin	36.13	38.46	47.61	45.78	49.73
Research & Development	138.49	135.3	170.92	170.27	160.85
Operating Expenses	174.62	173.76	218.53	216.05	210.58
Operating Income	-59.92	-173.76	-218.53	-216.05	-210.58
Interest Expense	-11.52	-13.51	-13.88	-19.44	-12.67
Interest & Investment Income	1.78	2	1.58	0.76	3.44
Other Non Operating Income (Expenses)	0.96	6.01	0.11	1.14	-0.08
EBT Excluding Unusual Items	-68.7	-179.27	-230.72	-233.59	-219.88
Gain (Loss) on Sale of Investments	13.06	9.45	1.41	-0.34	-0.1
Pretax Income	-55.64	-179.82	-229.38	-234	-243.36
Income Tax Expense	0.89	-	-	-	-
Net Income	-56.53	-179.82	-229.38	-234	-243.36
Net Income to Common	-56.53	-179.82	-229.38	-234	-243.36
Shares Outstanding (Basic)	226	153	85	75	69
Shares Outstanding (Diluted)	226	153	85	75	69
Shares Change (YoY)	48.23%	80.46%	13.00%	9.24%	25.16%
EPS (Basic)	-0.25	-1.18	-2.71	-3.13	-3.55
EPS (Diluted)	-0.25	-1.18	-2.71	-3.13	-3.55
Free Cash Flow	-3.47	-159.16	-187.44	-190.44	-177.86
Free Cash Flow Per Share	-0.01	-1.04	-2.22	-2.54	-2.60
Gross Margin	100.00%	-	-	-	-
Operating Margin	-52.24%	-	-	-	-
Profit Margin	-49.28%	-	-	-	-
Free Cash Flow Margin	-3.02%	-	-	-	-
EBITDA	-59.09	-172.15	-216.7	-214.31	-209.17
EBITDA Margin	-51.51%	-	-	-	-
D&A For EBITDA	0.83	1.61	1.83	1.74	1.41
EBIT	-59.92	-173.76	-218.53	-216.05	-210.58
EBIT Margin	-52.24%	-	-	-	-
Revenue as Reported	114.7	-	-	-	-

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q